加载中
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
收盘时
US$3.01
−US$0.09 · -2.90%
盘后
US$3.00
−US$0.01 · -0.33%
10月13日 16:35 ET
盘中时间采用ET。市场数据可能有所延迟。
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
日内区间
当前US$3.01
52周区间
当前US$3.01
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
45
合理估值
情绪
51
多空交织
风险
66
高风险
动量
19
强势下行
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Autonomix Medical, Inc., a development stage medical device company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. The company’s technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. It develops technology for patients with pancreatic cancer and addresses indications for chronic pain management, hypertension, cardiovascular, and other nerve-related disorders. Autonomix Medical, Inc. was incorporated in 2014 and is headquartered in The Woodlands, Texas.
日内区间
当前US$3.01
52周区间
当前US$3.01
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 销货成本 | 1.2万 USD | — | — | — | — |
| 毛利 | −1.2万 USD | — | — | — | — |
| 研究与开发 | 714.4万 USD | 472.5万 USD | 222.5万 USD | 74.5万 USD | 4069 USD |
| 销售、一般及管理费用 | 989万 USD | 686.3万 USD | 524.9万 USD | 124.5万 USD | 1359.02万 USD |
| 营业费用 | 1702.2万 USD | 1158.8万 USD | 1203万 USD | 199万 USD | 1359.43万 USD |
| 利息收入 | 31.9万 USD | 35.4万 USD | 12.7万 USD | — | — |
| 利息支出 | — | 17.6万 USD | 7.9万 USD | — | 21.81万 USD |
| 折旧和摊销 | 1.2万 USD | 18.3万 USD | 8.1万 USD | — | — |
| 营业利润 | −1703.4万 USD | −1158.8万 USD | −1203万 USD | −199万 USD | −1359.43万 USD |
| 净利润 | −1671.5万 USD | −1141万 USD | −1542.6万 USD | −199万 USD | −1332.87万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2026年6月24日 | 1:21 | — | — |
已生效 2026年6月24日
1:21
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
